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Introduction
Recent research has provided indications for a link between 
altered Gut Microbiota (GM) composition and the risk of chronic 
metabolic disorders and low grade inflammation, contributing 
to the pathogenesis of Type 2 diabetes (T2D) and cardiovascular 
diseases (CVD) [1-3]. It has been known for decades that diet plays 
an important role in the development of lifestyle related diseases, but 
the mechanisms are still insufficiently elucidated. The mammalian 
GM comprises approximately 1014 bacteria, representing about 1,000 
abundant bacterial species [4]. Its composition is influenced by several 
factors such as diet, health state and genetic predispositions [5,6]. The 
composition and metabolic activity of the GM is hypothesized to have 
an impact on gut permeability, systemic inflammation, and metabolic 
functions of the host [7,8]; it is, however, a major scientific challenge 
to establish the causalities driving the interactions between GM, host 
health, and environmental factors. 
It is established from both animal and human studies that dietary 
interventions affect the composition of the GM communities in a rapid 
Abstract
Background: Gut microbiota composition and activity may be changed by dietary factors and possibly affect 
metabolic health. Dietary gluten and wholegrain are suggested to influence metabolism in a negative and positive 
direction, respectively. 
Objective: Describe the design and rational as well as baseline characteristics of two human intervention studies, 
within the Gut, Grain and Greens (3G) Center, investigating the effects of a gluten-poor and wholegrain-rich diet on 
microbiota composition and metabolic health. 
Design: The gluten and wholegrain studies had a randomized, controlled, cross-over design each comprising two 
eight-week dietary intervention periods, separated by a six-week wash-out period. Each trial included 60 men and 
women exhibiting an increased metabolic risk. In the gluten study a gluten-poor diet was compared with a gluten-rich 
dietary fiber-controlled diet, and in the wholegrain study a wholegrain-rich diet was compared with a refined grain diet. 
The control diet was identical in both studies, being concomitantly high in gluten and refined. Participants substituted all 
cereal products with provided intervention products which they consumed ad libitum. Before and after each intervention 
period, fecal samples for quantitative metagenomic analyses were collected and an examination day was conducted. 
The primary outcome of the gluten intervention study was changes in the gut microbiota composition, while insulin 
sensitivity was an additional primary outcome of the wholegrain study. Further, a number of secondary outcomes were 
investigated.
Results: 52 and 50 participants completed the gluten and wholegrain intervention study, respectively. Participants 
had slightly elevated fasting glucose levels and increased waist circumference. Biological outcomes of the two studies 
will be published elsewhere.
Conclusion: The studies have the potential to provide new insights into the interplay of gut microbiota and metabolic 
health in individuals with increased risk of developing metabolic disorders.
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and diet specific manner [9-14], but knowledge about the role of diet 
on GM functionality in humans is still limited. Evidence reveals that 
several chronic disorders are characterized by a reduced intestinal 
bacterial diversity and that different GM enterotypes may be associated 
with long-term intake of protein, fat and carbohydrates [14]. Thus, 
it may be hypothesized that also dietary components such as gluten 
and wholegrain affect bacterial diversity within various taxa and 
enterotypes. 
Gluten is a structural protein component of wheat, rye and barley 
and present in high amounts in Western-type diets [15]. From in vitro 
models it is known that gluten is related to gut inflammation [16] 
and increased gut permeability [17]. Consumption of gluten has been 
linked to celiac disease in genetically pre-disposed individuals [16] and 
gut symptoms and fatigue in irritable bowel syndrome patients [18]. 
However, little is known about the effect of gluten on risk of chronic 
systemic low-grade inflammation in apparently healthy individuals. A 
recent study of ten healthy individuals consuming a gluten-free diet 
for one month observed alterations in GM composition and lowered 
immune response [19]. Wholegrain consumption has been associated 
with a decreased risk of T2D and CVD in prospective studies [20,21] 
and has been suggested to beneficially influence glucose metabolism 
[22], adiposity [23,24], and blood lipids [25,26]. Wholegrains have 
prebiotic effects, due to the high content of dietary fibers [27], which 
by microbial fermentation lead to production of short-chain fatty 
acids (SCFA) [28]. SCFA may exert metabolic effects on secretion of 
gut hormones [29], glucose and fat metabolism [30,31], low-grade 
inflammation [1], and gut permeability [32]. Most studies focused on 
specific dietary fibers and further investigation is needed to establish 
how a diet rich in various wholegrain foods affects GM composition 
and whether this is associated with changes in host metabolism. 
Here, the rationale and design of two human intervention studies 
on the effects of a gluten-poor and a wholegrain-rich diet on host-GM 
interactions and host health are described.
Methods
Two human intervention studies were performed as a part of the 
Center for Gut Microbiota, Metabolic disorders, and Grain/Fiber based 
Diets (3G: Gut, Grain and Greens, www.3g-center.dk ).The center 
aims to generate novel knowledge about the impact of specific dietary 
compounds on GM composition and function and host metabolic 
health by applying ’metagenomic sequencing’ and quantitative 
metagenomics as well as analysis of host metabolic variables.
The wholegrain study was conceived and managed by investigators 
from the Department of Nutrition, Exercise and Sports, Faculty of 
Science, University of Copenhagen (NEXS), while the gluten study 
was conceived and managed by investigators from the Novo Nordisk 
Foundation Center for Basic Metabolic Research, Faculty of Health and 
Medical Sciences, University of Copenhagen. Both trials were run in 
parallel at NEXS.
The studies applied a randomized, controlled, cross-over design 
comprising two dietary intervention periods of eight weeks duration, 
separated by a wash-out period of at least six weeks. A total of 60 
participants were included in each of the two trials. The outline 
of the studies is presented in Figure 1. The gluten and wholegrain 
study were registered at www.clinicaltrials.gov (NCT01719913 and 
NCT01731366, respectively) and were approved by the Municipal 
Ethical Committee of the Capital Region of Denmark in accordance 
with the Helsinki declaration (H-2-2012-064 and H-2-2012-065, 
respectively) and the Data Protection Agency (2012-54-0170 and 2007-
54-0269, respectively).
Hypotheses
The 3G center investigates the hypothesis that interplays between 
human host and GM affect the risk of chronic metabolic disorders and 
that interventions targeting the GM modulate the risk of developing 
metabolic dysfunctions. 
Figure 1: Study outline.
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Hypotheses of gluten intervention
1)	 Compared to a gluten-rich diet a gluten-poor diet induces 
changes of GM composition and functional potential. 
2)	 Compared to a gluten-rich diet a gluten-poor diet beneficially 
influences host metabolic and inflammatory markers. These 
changes in host physiology correlate with dietary gluten-
related changes in GM.
3)	 Compared to a gluten-rich diet a gluten-poor diet lowers 
gastrointestinal permeability. 
4)	 Compared to a gluten-rich diet a gluten-poor diet causes less 
subjective gastrointestinal discomfort.
Hypotheses of wholegrain intervention
1)	 A wholegrain-rich diet improves insulin sensitivity, which is 
associated with increased richness and diversity of the GM, and 
increased levels of saccharolytic bacteria and SCFA formation. 
2)	 A wholegrain-rich diet improves postprandial glucose 
tolerance and appetite regulation and reduces food intake and 
adiposity via effects on colonic fermentation. 
3)	 A wholegrain-rich diet reduces total and LDL-cholesterol.
Common hypotheses
1)	 Intake of a gluten-poor or wholegrain-rich diet has immune-
modulatory effects linked to changes in the inflammasome 
and cytokine levels (e.g. IL-1β, TNF-α, and IL-6), mediated by 
changes in gut permeability and GM composition.
2)	 Wholegrains are rich in methyl donor components (e.g. 
B-vitamins), while a gluten-deprived diet is vastly depleted of 
methyl donors; thus, these two diets are hypothesized to have 
opposite effects on markers of methylation capacity, which 
may via different pathways affect metabolic syndrome markers.
Primary and Secondary Outcomes
In the gluten protocol an altered GM composition and functional 
potential during consumption of a gluten-poor compared to a gluten-
rich diet is the primary endpoint. This endpoint is determined by 
quantitative metagenomic analyses of microbial DNA isolated from 
stool samples and sequenced applying a combination of deep and 
untargeted shotgun sequencing, 16S gene-targeted sequencing, and for 
selected bacterial taxa real-time qPCR.
In the wholegrain protocol, besides an altered GM composition, 
altered insulin sensitivity, as estimated by the Homeostasis Model 
Assessment of fasting Insulin Resistance (HOMA-IR), is an additional 
relevant primary outcome. 
Both studies comprise a number of secondary outcomes including 
selected measures of glucose and lipid metabolism, gut functionality 
(intestinal transit time, gastrointestinal symptoms, defecation patterns, 
and gut permeability), inflammatory markers (plasma cytokine levels, 
immune cell composition and surface marker, and ex vivo cytokine 
responses), appetite regulation and food intake, anthropometry (body 
weight, waist circumference, sagittal abdominal diameter, and body 
composition), blood pressure, markers of methylation, immune cell 
transcriptomics, and urine and plasma metabolomics.
Participants
Inclusion and exclusion criteria
Individuals were invited to participate in one of the two studies 
at random and recruitment for each study was stopped once 60 
participants were randomized in each of the two protocols. The 
participants had to be Danish-speaking men and women exhibiting 
a metabolic “risk profile”. In order to participate they had to meet a 
total of four compulsory inclusion criteria as well as at least one of four 
additional inclusion criteria: 
Compulsory inclusion criteria: 
•	 Age 20 - 65 years 
•	 Apparently healthy
•	 BMI 25-35 kg/m2 or waist circumference ≥ 94 cm for men and 
≥ 80 cm for women
•	 Weight stable
Additional inclusion criteria: 
•	 Fasting plasma glucose 6.1- 6.9 mmol/L
•	 Fasting serum HDL-cholesterol ≤ 1.03 mmol/L for men and ≤ 
1.29 mmol/L for women
•	 Fasting plasma triacylglycerol >1.3 mmol/L
•	 Systolic blood pressure >130 mmHg or medical treatment of 
hypertension 
Exclusion criteria: 
•	 Diagnosis of chronic GI disorders, diabetes or chronic 
pancreatitis
•	 Pharmacological treatment of dyslipidemia 
•	 Medically prescribed diet
•	 Antibiotic treatment (<3 months prior to study start) or intake 
of pre- or probiotic supplements (< 1 month prior to study 
start)
•	 Blood hemoglobin <7.0 mmol/L or blood donation <1 month 
prior to study start or intention to do so during study
•	 Participation in other biomedical trials (<1 month prior to 
study start)
•	 Pregnancy (<3 months prior to study start) or lactation (<6 
weeks prior to study start)
•	 Intense physical activity ( >10 h/week)
•	 Alcohol consumption >21 units/week for men and >14 units/
week for women
In order to detect latent celiac diseases, levels of serum IgA and IgG 
transglutaminase were measured as a marker of celiac diseases at the 
first examination day. In case values exceeded the acceptable maximum 
(>8 units/mL for IgA and >10 units/mL for IgG) participants were 
excluded from the study. Participants for the gluten and wholegrain 
intervention were initially recruited from the general population studies 
“Health 2008” and “Health 2010”, established at the Research Center 
for Prevention and Health (RCPH) at Glostrup University Hospital in 
Copenhagen, Denmark [33,34]. RCPH provided information on age, 
sex, anthropometry, and fasting values on blood glucose, triglycerides, 
and HDL-cholesterol of all participants. Eligible candidates, i.e. 
fulfilling the inclusion criteria, were contacted through an information 
letter encouraging them to contact NEXS by e-mail or telephone. Half 
of the eligible candidates received letters for the gluten and half for the 
wholegrain study. After approximately two weeks, persons who had 
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not contacted NEXS were contacted by telephone by the study staff to 
learn about their potential interest in participation. As an insufficient 
number of participants from the “Health 2008” and “Health 2010” 
cohorts were recruited, additional participants were recruited through 
the webpage www.forsøgsperson.dk as well as through advertisements 
in local newspapers.
Screening
Interested individuals who had participated in the general 
population studies were screened via telephone for compulsory 
inclusion and exclusion criteria. Individuals recruited through 
advertisement were also pre-screened by telephone. Subjects fulfilling 
the compulsory inclusion criteria and taking blood pressure lowering 
medicine were directly included in the study, otherwise they were 
invited for an instant measurement of their blood pressure. Individuals 
were included if the systolic blood pressure was >130 mmHg (3 repeated 
measures), otherwise they were screened for increased fasting plasma 
glucose, decreased fasting serum HDL-cholesterol, and increased 
fasting plasma triacylglycerol concentrations. 
Informed consent
All individuals received written information and were invited to an 
information meeting, which was held separately for the wholegrain and 
gluten intervention study. During these meetings potential participants 
received extensive information on background and study procedures 
and afterwards written informed consent was obtained. 
Before study start, participants attended a preparation meeting, 
where they were instructed on all study procedures that needed to be 
undertaken prior to the first examination day, i.e. four-day dietary 
registration, feces collection, and fasting procedure before examination 
days as well as intake of plastic markers and completion of a defecation 
diary. Further, hemoglobin concentration was assessed by a finger-
prick measurement, to ensure that individuals with low hemoglobin 
values (<7 mmol/L) were not subjected to blood sampling.
Randomization, Allocation, Concealment and Blinding
In each study, 60 participants were randomized at the first 
examination day. Randomization was performed separately 
for each of the studies in blocks of variable size to ensure equal 
randomization throughout the enrolment phase of the study. The 
randomization sequence was made by an investigator without contact 
to the participants (www.radomization.com). The dietitian allocated 
participants to the sequence of intervention using a list of participant 
IDs matched with allocated sequences. Both, the participants and the 
investigators involved in outcome assessment were blinded until the 
first examination day. Thereafter, blinding was not feasible due to 
the nature of the intervention. However, blinding of the allocation 
sequence will be re-established during sample analysis and initial data 
analysis. 
Interventions
In the gluten study the aim was to keep the daily gluten consumption 
to an absolute minimum in the gluten-poor period (<2 g/d) and as high 
as possible in the control period (>20 g/d). The average consumption 
of gluten among Danish adults is uncertain, however assuming 
comparability with the Dutch population, an average intake of 11 g 
gluten per day is suggested (34). All cereals for the gluten-poor period 
were gluten-free or contained marginal traces of gluten. The wholegrain 
study aimed for a daily consumption of ≥ 75 g/d of wholegrain during 
the wholegrain period and of <10 g/d in control period, corresponding 
to the 90th and 10th percentile of the population, respectively. 
Wholegrain cereals consist of the intact, ground, cracked, or flaked 
caryopses, where the starchy endosperm, germ, and bran are present in 
the same relative proportions as in the intact caryopsis according to the 
definition proposed by the HEALTHGRAIN consortium in 2013 [35]. 
All wholegrain foods used contained a minimum of 50 % of wholegrain 
per dry matter.
Study products 
Participants were provided with a selection of cereal products, 
corresponding to intervention type and period. Participants were 
advised to replace all cereal products from their diet with the provided 
study products, which were consumed ad libitum. The study products 
were aimed to be compatible with a typical Danish diet and comprised 
different kinds of cereal flakes and rolled oats for breakfast, breads for 
lunch, pasta, kernels, rice and bulgur for dinner, and crisp breads for 
snacks. The two studies had different active intervention diets (gluten-
poor or wholegrain, respectively), whereas the control diets in both 
studies were comprised of the same products (Table 1). The gluten-
poor and the control diet were matched for dietary fiber content, in 
order to exclude dietary fiber as a potential confounder. 
To ensure complete substitution of cereal products and to limit 
gluten intake from the background diet, participants were not allowed 
to consume any cereal products besides the provided study products. 
This also included flour-containing confectioneries, such as cakes and 
biscuits, and savory snacks. Further, flour-based “fast food” meals as 
well as ready-to-eat meals, such as pasta and lasagna, were restricted. 
Moreover, participants were asked not to consume starchy products, 
such as potatoes, more than once a week, as they might consume 
these products instead of the provided study products. The same 
dietary restrictions were applied in both studies in order to ensure 
comparability between studies. 
Consumption of study products
A trained dietitian provided participants with instructions on how 
to incorporate the provided study products in the diet. Initially it was 
ensured that study products were provided in sufficient amounts to 
ensure ad libitum consumption. Thereafter, participants were provided 
individualized amounts of all study products every second week to 
Gluten-poor Wholegrain Control
Product (Brand) Product (Brand) Product (Brand)
•	 Cornflakes (COOP)
•	 Oat flakes (AXA)
•	 Gluten-free rye bread (Specialbageren)
•	 Gluten-free home baked buns (FINAX)
•	 Gluten-free pasta (Doves Farm)
•	 Quinoa (Urtekram)
•	 Rice (NorgesGruppen)
•	 Gluten-free crisp bread (Wasa)
•	 Rolled Oats (Lantmännen)
•	 Oat flakes (AXA)
•	 Wholegrain rye kernel bread (Kohberg)
•	 Wholegrain wheat buns (Kohberg)
•	 Wholegrain wheat pasta (Kungsörnen)
•	 Wheat kernel (Lantmännen)
•	 Wholegrain bulgur (Zelected foods)
•	 Wholegrain rye crisp bread (Wasa)
•	 Wheat-rice flakes (Kelloggs)
•	 Oat flakes (AXA)
•	 Maslin bread (Kohberg)
•	 Wheat buns (Kohberg)
•	 Wheat pasta (Lantmännen)
•	 Pearled spelt (Lantmännen)
•	 Bulgur (Unifood)
•	 Crisp bread (Wasa)
Table 1: Intervention products consumed ad libitum for substituting all dietary cereal products during the studies.
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meet their personal choices and preferences. All breads and buns were 
provided as frozen products, and all foods were either delivered to the 
participants at their home or picked up at NEXS, if more convenient.
Compliance
Participants were instructed to keep a study diary, in which they 
registered daily consumption (amount and type) of study products 
throughout both intervention periods. Furthermore, participants 
noted any deviations from the dietary instructions in the diary. Any 
cases of illness or use of medication, including antibiotics, during the 
study periods were also noted in the study diary. The study diary was 
used as a measure of compliance to the intervention and to calculate 
absolute consumption of study products. A trained dietician conducted 
a follow-up telephone-call every second week prior to home delivery 
of study products, focusing on consumption of study products and 
adherence to the diet.
Study Examinations
Examination days were conducted at the beginning and in the end 
of each intervention period. All examinations were done at NEXS. 
Before each examination day, participants had to collect a fecal sample, 
divide it into one fresh (stored at 5°C) and one immediately frozen sub-
sample, and bring them to NEXS.
Before examination days 1, 2 and 4 participants ingested non-
absorbable radio-opaque transit markers for measurement of intestinal 
transit time and filled in a defecation diary for six consecutive days. 
Furthermore, they completed a four-day pre-coded dietary registration, 
developed by the National Food Institute at the Technical University of 
Denmark [36,37]. 
Participants arrived at NEXS in the morning after having fasted 
for at least ten hours and abstained from physical activity and alcohol 
consumption for ≥ 24 hours. Additionally, participants were asked to 
avoid smoking and tooth brushing in the morning of the examination 
day. A fasting blood sample was drawn, blood pressure and all 
anthropometric measurements (sagittal abdominal diameter, waist 
circumference, body weight and composition) were assessed and a 
saliva and nasal fluid sample were collected. Hereafter, the participants 
were provided a drink containing lactulose and mannitol as urinary 
excretion of these sugars reflects gut permeability. A minimum 4 h urine 
sample was collected for this purpose. Subsequently, a standardized 
breakfast, consisting of white wheat bread, a pastry, butter, jam, 
cheese and 200 ml water (approximately 3000 kJ, 52.6 E% fat, 39.7 
E% carbohydrates, 7.8 E% protein), was served and postprandial 
blood samples were drawn at 30, 60, 120, and 180 min, followed by 
an ad libitum lunch meal. Subjective appetite sensation, using Visual 
Analogue Scales (VAS), and breath hydrogen excretion were measured 
twice at fasting, and every 30 min following the standardized breakfast. 
Furthermore, participants rated their GI symptoms during the past 
week and provided information on intake of medications and dietary 
supplements. At examination days 1, 2, and 4 an X-ray of the abdomen 
was taken during the afternoon at Frederiksberg Hospital, Copenhagen, 
Denmark. All procedures are summarized in Table 2.
Laboratory analyses
Throughout all the sample analysis procedures, samples will be 
randomized across time-points; however, all samples from a single 
individual will be analyzed in the same batch in order to minimize 
intra-individual variation. GM will be analyzed by a comprehensive 
combination of shotgun metagenome sequencing, 16S gene-targeted 
sequencing, and real-time PCR of selected bacterial taxa.
Status of trials
Recruitment was initiated in July 2012, and all data collection, 
i.e. completion of intervention and examination days, was completed 
in November 2013. Currently, biochemical analyses are ongoing; 
however, analyses of the GM composition are not expected to be 
finished before 2015. 
Statistical Considerations 
Sample size estimation
Prior to recruitment the sample size estimations were calculated. 
For the gluten protocol estimations were based on 85 % statistical 
power to detect a difference of 0.4 standard deviation in metabolic 
quantitative traits, based on previous observations from the MetaHit 
study [38]. It was estimated that 51 individuals were needed, but to 
allow for a 15 % drop-out after randomization, a total of 60 participants 
were invited for participation. Overall the number of subgroups within 
each arm of the study is still blinded, but the MetaHit estimation of 
three major enterotypes, should be addressable with the current setup. 
The sample size for the wholegrain protocol was estimated based on 
an expected difference in HOMA-IR between the wholegrain and the 
control periods of 0.25 with a weighted standard deviation of 0.6. The 
expected difference was based on an average difference of 0.26 among 
three difference studies [22,25,39]. The weighted standard deviation of 
0.6 was based on unpublished data on within-group variation of 0.52 
and 0.72 in refined grain and WG groups, respectively, from the study 
Examination 1 Examination 2 Examination 3 Examination 4
Blood pressure + + + +
Anthropometrics + + + +
Meal challenge + + + +
Blood (0, 30, 60, 120, 180 min after meal challenge) + + + +
Breath hydrogen (8 times) + + + +
Appetite (8 times) + + + +
Saliva and nasal fluid + + + +
4h urine + + + +
Feces + + + +
GI-symptoms + + + +
4-days dietary registration + + - +
Transit time (X-ray) + + - +
Ad libitum meal + + + +
Abbreviations: VAS: visual analogue scales; La/Ma: lactulose/mannitol; GI: gastrointestinal
Table 2: Measurements performed before and during examination days 1, 2, 3 and 4.
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by Kristensen et al. 2012. When applying a 5 % significance level and 
85 % statistical power, a sample size of 51 participants was needed. A 
15 % drop-out after randomization was assumed, thus a total of 60 
participants were invited to participation. 
Analysis of primary and secondary outcomes
All data will be checked for normal distribution and homogeneity 
of variance. In case of non-normal distributions, data transformation 
will be attempted or non-parametric analyses applied. All analyses will 
be performed as completers case analyses as imputations for drop-outs 
is not considered feasible for many of the outcomes, also considering 
the cross-over design. GM composition data will be analyzed as 
previously reported [38].
Analysis of HOMA-IR and fasting biochemical variables, such as 
insulin, glucose and plasma cholesterol as well as body weight will be 
analyzed as randomized, meaning only considering the baseline value 
and the sequence of treatments. Subsequent analyses will be performed 
adjusting for relevant covariates, such as sex, age, and markers of health 
and nutritional status (e.g. BMI). In the wholegrain intervention body 
weight change will furthermore be analyzed in term of responders and 
non-responders. Potential differences between the effects in men and 
women will be tested by inclusion of a group-gender interaction term 
as well as by sub-group analyses. Effect on insulin, glucose and other 
metabolic outcomes will also be analyzed in sub-groups for individuals 
with high and low baseline levels.
For the primary outcome GM composition the genetic material 
(DNA) of each individual stool sample will be extracted following 
protocols established during the MetaHIT project (www.metahit.
eu) and WGS sequenced using current Next-Generation sequencing 
technology (Illumina HiSeq, 100bp pair end, 300-400bp insert size). 
It is aimed at 6Gbp raw sequence data for each sample, resulting in 
ca. 720 gigabases microbiome sequence data. As human faces usually 
contain only a very small amount of human DNA, removal of non-
microbial DNA will be performed in-sillico. DNA from each sample 
will undergo de novo assembly, gene calling and taxonomical as well 
as functional annotation, using pipelines established in the MetaHIT 
project. This will allow establishment of a 3G specific microbial gene 
catalogue, which will be compared and integrated with the previously 
established gene catalogues for Danish, Spanish, and Chinese 
populations [4,40]. All genes in the gene catalogue will be binned by 
co-abundance to identify co-varying gene modules and Co-Abundance 
gene groups (CAG) [40]. This new 3G  specific microbial gene and 
genomes catalogue will then be used to identify genes, genomes and 
genetic modules as markers which associate to phenotypic outcome. 
Additionally, the cohort will be stratified into cohort Enterotypes [41] 
and patterns of microbial diversity in relation to diet.
Exploratory analysis for the metabolic outcomes will be conducted 
and changes in metabolic outcomes will also be correlated with 
compliance. Other outcomes will be analyzed according to the same 
principles using models with repeated measurement in the analysis of 
postprandial data, such as responses in glucose, insulin, and appetite 
hormones as well as subjective appetite sensation, GI-symptoms, gut 
permeability, inflammatory markers, and breathe hydrogen excretion.
Results
Sixty participants were randomized in each of the studies. A 
total of 52 and 50 participants completed the gluten and wholegrain 
intervention study, respectively. The flow of participants is depicted in 
Figure 2.
There were more women than men in both studies. Baseline data 
of participants recruited for the gluten and wholegrain intervention 
studies are presented in Tables 3 and 4, respectively. All participants 
who dropped out did so before entering the second intervention period, 
and most withdrawals were related to either examination procedures 
or intervention products. 
Overall, participants in both studies had slightly elevated fasting 
glucose levels according to the glucose regulation definitions of the 
American Diabetes Association [42] and increased waist circumference 
according to International Diabetes Federation [43]. For both studies, 
there were found no significant differences between randomization 
groups at baseline. 
Discussion
To the authors’ knowledge, the presented intervention protocols 
on gluten and wholegrain, respectively, are the largest studies to 
date examining the effects of both dietary gluten-withdrawal and 
wholegrain-addition on metabolic health markers and changes in the 
GM composition in a metabolic at-risk population. Participants in 
both studies were apparently and by self-report healthy individuals, 
yet with an elevated metabolic risk, due to increased adiposity. This 
renders the study population an optimal target group for investigating 
potential health improvements resulting from dietary gluten reduction 
or increased wholegrain consumption.
The main objective of the human intervention studies was to 
examine the effect of the dietary gluten deprivation or the increased 
intake of wholegrain on changes in the GM composition and associate 
this with changes in whole-body insulin sensitivity, measured as 
HOMA-IR, as well as changes in a large number of other host metabolic 
variables. Fecal samples were collected and bacterial DNA will be 
extracted, sequenced and analyzed applying the state of the art methods 
also used in the MetaHit project [4,41], which will provide extensive 
information on the GM composition. Additionally, untargeted shot-
gun sequencing and targeted 16S-rRNA gene sequencing will be 
supplemented by quantitative PCR based determination of selected 
relevant bacterial taxa [44]. In an integrated approach, using complex 
bioinformatic methods, GM and metabolic health variables will be 
analyzed, giving new insights into the interactions between GM and 
host metabolic health. It needs to be noted that data from human 
interventions not involving GM transplantation will never per se allow 
an absolute establishment of causalities in the interplay between GM 
and host health. However, given the design of studies, comprising two 
interventions with very different expected effects, the possibilities to 
identify truly linked events will strongly increase. Furthermore, the 
integrated 3G research program also comprises animal trials involving 
transfer of human fecal samples from the two intervention studies to 
germ-free mice in order to uncover potential causal relations. 
In both studies, all cereal products in the participants’ diet were 
substituted with the provided study products, whereas it was aimed to 
keep the background diet the same during all periods. Thus, changes 
in metabolic variables as well as the GM composition are likely the 
direct consequence of the dietary interventions. As participants also 
daily registered the type and amount of study products consumed, 
correlations of particular products, e.g. wholegrain rye vs. wholegrain 
wheat, with certain health estimates and gut bacteria can be explored. 
Control diets in the two studies were identical and the same dietary 
restrictions were applied during all study periods allowing direct 
comparisons of the intervention periods within each study as well as 
between the two studies.
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So far, studies of a gluten-poor diet on health and GM have been 
limited in healthy individuals with varying degrees of adiposity [19], 
thus the gluten study will provide new evidence on the effects of gluten 
on a variety of inflammatory and metabolic variables in non-celiac 
individuals as well as on GM composition. In contrast, numerous 
studies have investigated health effects of wholegrain consumption, 
such as insulin sensitivity, adiposity, and inflammation [6,25,26]. 
However, results are inconsistent, which may be due to differences in 
study designs and lack of statistical power. Changes in GM composition 
as a consequence of wholegrain consumption have been investigated 
before; however, only focusing on selected bacterial groups [45]. 
One of the strengths of the studies described here is the high 
statistical power, which, due to the large sample size and the cross-
over design, allows detecting even small differences in the outcome 
variables. It can be debated whether small differences are of clinical 
relevance; however, it may be relevant in a public health perspective for 
prevention of lifestyle diseases. Furthermore, an increased power of the 
studies enhances the chance of associating changes in host health with 
changes in GM composition and functionality. Deliberately, the two 
studies did not focus on specific products or cereal types, but rather 
provided a variety of different cereals and products. Due to this and 
the ad libitum consumption of products, the studies reflect realistic 
patterns of consumption, which will render the results more applicable 
to the Danish population.
Conclusion
The gluten and wholegrain studies have the potential to provide new 
insights into the interplay of GM and metabolic health in individuals 
with increased risk of progressing to metabolic disorders. 
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